JP Patent

JP5465005B2 — マントル細胞リンパ腫治療のための３−（４−アミノ−１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−ピペリジン−２，６−ジオンの使用

Assigned to Celgene Corp · Expires 2014-04-09 · 12y expired

What this patent protects

Patent listed against Revlimid.

Drugs covered by this patent

Patent Metadata

Patent number
JP5465005B2
Jurisdiction
JP
Classification
—
Expires
2014-04-09
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.